TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD DisclosureItem 7.01
Tonix Pharmaceuticals Holding Corp. (the “Company”) updated its investor presentations, which are used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. Copies of the presentations are filed as Exhibit 99.01, 99.02 and 99.03 hereto and incorporated herein by reference.
On April 3, 2018, the Company issued a press release announcing that 50% of the planned total number of participants in the Phase 3 HONOR study evaluating Tonmya®, or TNX-102 SL 5.6 mg, for the bedtime treatment of military-related posttraumatic stress disorder, have been randomized. A copy of the press release is filed as Exhibit 99.04 hereto and incorporated herein by reference.
The information in this Current Report, including all exhibits, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing, and is not deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
* Furnished herewith.
Tonix Pharmaceuticals Holding Corp. ExhibitEX-99.01 2 s109538_ex99-01.htm EXHIBIT 99.01 Exhibit 99.01 © 2018 Tonix Pharmaceuticals Holding Corp. April 2018 Version P0106 4 – 3 – 18 (Doc 0334) Investor Presentation © 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward – Looking Statements Certain statements in this presentation regarding strategic plans,…To view the full exhibit click here